J&J steps up vaccines R&D—and preps for launches—with €72M plant

Johnson & Johnson has big ambitions in vaccines, and to get there, its manufacturing has to measure up. The small plant acquired in its Crucell purchase just won't support its advancing pipeline candidates—and certainly not product launches down the road.